請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36640完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 劉振軒(Chen-Hsuan Liu) | |
| dc.contributor.author | Chiao-Ling Hung | en |
| dc.contributor.author | 洪巧凌 | zh_TW |
| dc.date.accessioned | 2021-06-13T08:09:02Z | - |
| dc.date.available | 2012-07-27 | |
| dc.date.copyright | 2011-07-27 | |
| dc.date.issued | 2011 | |
| dc.date.submitted | 2011-07-20 | |
| dc.identifier.citation | 1 Aaronson RM, Graven KK, Tucci M, McDonald RJ, Farber HW: Non-neuronal enolase is an endothelial hypoxic stress protein. J Biol Chem 270: 27752-27757, 1995
2 Abadie JJ, Amardeilh MA, Delverdier ME: Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. J Am Vet Med Assoc 215: 1629-1634, 1999 3 al-Sarraf R, Mauldin GN, Patnaik AK, Meleo KA: A prospective study of radiation therapy for the treatment of grade 2 mast cell tumors in 32 dogs. J Vet Intern Med 10: 376-378, 1996 4 Alberati-Giani D, Cesura AM, Broger C, Warren WD, Rover S, Malherbe P: Cloning and functional expression of human kynurenine 3-monooxygenase. FEBS Lett 410: 407-412, 1997 5 Auxilia ST, Hill PB: Mast cell distribution, epidermal thickness and hair follicle density in normal canine skin: possible explanation for the predilection sites of atopic dermatitis? Vet Dermatol 11: 247-254, 2000 6 Baker-Gabb M, Hunt GB, France MP: Soft tissue sarcomas and mast cell tumours in dogs; clinical behaviour and response to surgery. Aust Vet J 81: 732-738, 2003 7 Bostock DE: Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br Vet J 142: 1-19, 1986 8 Bostock DE: The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract 14: 27-41, 1973 9 Bostock DE, Crocker J, Harris K, Smith P: Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours. Br J Cancer 59: 915-918, 1989 10 Cahalane AK, Payne S, Barber LG, Duda LE, Henry CJ, Mauldin GE, Frimberger AE, Cotter SM, Moore AS: Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated surgically with or without adjunctive treatment: 68 cases (1994-2002). J Am Vet Med Assoc 225: 401-408, 2004 11 Capello M, Ferri-Borgogno S, Cappello P, Novelli F: alpha-enolase: a promising therapeutic and diagnostic tumor target. FEBS J 278: 1064-1074, 12 Carpenedo R, Chiarugi A, Russi P, Lombardi G, Carla V, Pellicciari R, Mattoli L, Moroni F: Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. Neuroscience 61: 237-243, 1994 13 Chaffin K, Thrall DE: Results of radiation therapy in 19 dogs with cutaneous mast cell tumor and regional lymph node metastasis. Vet Radiol Ultrasound 43: 392-395, 2002 14 Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, Liu HK, Luh KT, Hsu LH, Wu CW, Ting CC, Chen CY, Chen KC, Yang TY, Chou TY, Wang WH, Whang-Peng J, Shih NY: Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res 12: 5746-5754, 2006 15 Chang YS, Wu WG, Walsh G, Hong WK, Mao L: Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clinical Cancer Research 9: 3641-3644, 2003 16 Chaudhary D, Miller DM: The c-myc promoter binding protein (MBP-1) and TBP bind simultaneously in the minor groove of the c-myc P2 promoter. Biochemistry 34: 3438-3445, 1995 17 Cohen Z, Ehret M, Maitre M, Hamel E: Ultrastructural analysis of tryptophan hydroxylase immunoreactive nerve terminals in the rat cerebral cortex and hippocampus: their associations with local blood vessels. Neuroscience 66: 555-569, 1995 18 Columbo M, Horowitz EM, Botana LM, MacGlashan DW, Jr., Bochner BS, Gillis S, Zsebo KM, Galli SJ, Lichtenstein LM: The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol 149: 599-608, 1992 19 Daeron M, Sterk AR, Hirata F, Ishizaka T: Biochemical analysis of glucocorticoid-induced inhibition of IgE-mediated histamine release from mouse mast cells. J Immunol 129: 1212-1218, 1982 20 Dastych J, Metcalfe DD: Stem cell factor induces mast cell adhesion to fibronectin. J Immunol 152: 213-219, 1994 21 Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002 22 Derenzini M: The AgNORs. Micron 31: 117-120, 2000 23 Dobson J, Cohen S, Gould S: Treatment of canine mast cell tumours with prednisolone and radiotherapy. Vet Comp Oncol 2: 132-141, 2004 24 Dobson JM, Scase TJ: Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. J Small Anim Pract 48: 424-431, 2007 25 Dowling P, Meleady P, Dowd A, Henry M, Glynn S, Clynes M: Proteomic analysis of isolated membrane fractions from superinvasive cancer cells. Biochim Biophys Acta 1774: 93-101, 2007 26 Downing S, Chien MB, Kass PH, Moore PE, London CA: Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 63: 1718-1723, 2002 27 Erickson JB, Flanagan EM, Russo S, Reinhard JF, Jr.: A radiometric assay for kynurenine 3-hydroxylase based on the release of 3H2O during hydroxylation of L-[3,5-3H]kynurenine. Anal Biochem 205: 257-262, 1992 28 Feo S, Arcuri D, Piddini E, Passantino R, Giallongo A: ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS Lett 473: 47-52, 2000 29 Fulcher RP, Ludwig LL, Bergman PJ, Newman SJ, Simpson AM, Patnaik AK: Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 228: 210-215, 2006 30 Galli SJ, Zsebo KM, Geissler EN: The kit ligand, stem cell factor. Adv Immunol 55: 1-96, 1994 31 Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984 32 Gieger TL, Theon AP, Werner JA, McEntee MC, Rassnick KM, DeCock HE: Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001). J Vet Intern Med 17: 687-692, 2003 33 Gordon JR, Burd PR, Galli SJ: Mast cells as a source of multifunctional cytokines. Immunol Today 11: 458-464, 1990 34 Govier SM: Principles of treatment for mast cell tumors. Clin Tech Small Anim Pract 18: 103-106, 2003 35 Gregory-Bryson E, Bartlett E, Kiupel M, Hayes S, Yuzbasiyan-Gurkan V: Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11. BMC Cancer 10: 559, 36 Grier RL, Di Guardo G, Myers R, Merkley DF: Mast cell tumour destruction in dogs by hypotonic solution. J Small Anim Pract 36: 385-388, 1995 37 Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R: Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 17: 455-461, 2004 38 Hansen HH, Briem T, Dzietko M, Sifringer M, Voss A, Rzeski W, Zdzisinska B, Thor F, Heumann R, Stepulak A, Bittigau P, Ikonomidou C: Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiol Dis 16: 440-453, 2004 39 Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710, 2003 40 Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, Kitamura Y: Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 193: 505-510, 2001 41 Holtze M, Saetre P, Erhardt S, Schwieler L, Werge T, Hansen T, Nielsen J, Djurovic S, Melle I, Andreassen OA, Hall H, Terenius L, Agartz I, Engberg G, Jonsson EG, Schalling M: Kynurenine 3-monooxygenase (KMO) polymorphisms in schizophrenia: an association study. Schizophr Res 127: 270-272, 42 Hottendorf GH, Nielsen SW: Pathologic report of 29 necropsies on dogs with mastocytoma. Pathol Vet 5: 102-121, 1968 43 Howard EB, Sawa TR, Nielsen SW, Kenyon AJ: Mastocytoma and gastroduodenal ulceration. Gastric and duodenal ulcers in dogs with mastocytoma. Pathol Vet 6: 146-158, 1969 44 Iemura A, Tsai M, Ando A, Wershil BK, Galli SJ: The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol 144: 321-328, 1994 45 Ishiguro T, Kadosawa T, Takagi S, Kim G, Ohsaki T, Bosnakovski D, Okumura M, Fujinaga T: Relationship of disease progression and plasma histamine concentrations in 11 dogs with mast cell tumors. J Vet Intern Med 17: 194-198, 2003 46 Iwata N, Ochiai K, Kadosawa T, Takiguchi M, Umemura T: Canine extracutaneous mast-cell tumours consisting of connective tissue mast cells. J Comp Pathol 123: 306-310, 2000 47 Jaffe MH, Hosgood G, Taylor HW, Kerwin SC, Hedlund CS, Lopez MK, Davidson JR, Miller DM, Paranjpe M: Immunohistochemical and clinical evaluation of p53 in canine cutaneous mast cell tumors. vet pathol 37: 40-46, 2000 48 Kemp JA, McKernan RM: NMDA receptor pathways as drug targets. Nat Neurosci 5 Suppl: 1039-1042, 2002 49 Kiupel M, Webster JD, Bailey KL, Best S, DeLay J, Detrisac CJ, Fitzgerald SD, Gamble D, Ginn PE, Goldschmidt MH, Hendrick MJ, Howerth EW, Janovitz EB, Langohr I, Lenz SD, Lipscomb TP, Miller MA, Misdorp W, Moroff S, Mullaney TP, Neyens I, O'Toole D, Ramos-Vara J, Scase TJ, Schulman FY, Sledge D, Smedley RC, Smith K, P WS, Southorn E, Stedman NL, Steficek BA, Stromberg PC, Valli VE, Weisbrode SE, Yager J, Heller J, Miller R: Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. vet pathol 48: 147-155, 50 Kiupel M, Webster JD, Miller RA, Kaneene JB: Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours. J Vet Med A Physiol Pathol Clin Med 52: 280-286, 2005 51 Kobayashi TK, Yakushiji M: Gastric carcinoma metastatic to the bone marrow: immunoperoxidase identification of KMO-1 antigen in MGG-destained aspirate. Diagn Cytopathol 7: 597-600, 1991 52 Kravis LD, Vail DM, Kisseberth WC, Ogilvie GK, Volk LM: Frequency of argyrophilic nucleolar organizer regions in fine-needle aspirates and biopsy specimens from mast cell tumors in dogs. J Am Vet Med Assoc 209: 1418-1420, 1996 53 Kube P, Audige L, Kuther K, Welle M: Distribution, density and heterogeneity of canine mast cells and influence of fixation techniques. Histochem Cell Biol 110: 129-135, 1998 54 Lasota J, Miettinen M: Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 53: 245-266, 2008 55 Lee CH, Liang CW, Espinosa I: The utility of discovered on gastrointestinal stromal tumor 1 (DOG1) antibody in surgical pathology-the GIST of it. Adv Anat Pathol 17: 222-232, 2010 56 Letard S, Yang Y, Hanssens K, Palmerini F, Leventhal PS, Guery S, Moussy A, Kinet JP, Hermine O, Dubreuil P: Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res 6: 1137-1145, 2008 57 Lo Presti M, Ferro A, Contino F, Mazzarella C, Sbacchi S, Roz E, Lupo C, Perconti G, Giallongo A, Migliorini P, Marrazzo A, Feo S: Myc promoter-binding protein-1 (MBP-1) is a novel potential prognostic marker in invasive ductal breast carcinoma. PLoS One 5: e12961, 2010 58 Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P: Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 9: 445-452, 2009 59 London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN: Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 27: 689-697, 1999 60 London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM: Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 9: 2755-2768, 2003 61 London CA, Kisseberth WC, Galli SJ, Geissler EN, Helfand SC: Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours. J Comp Pathol 115: 399-414, 1996 62 London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM: Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 15: 3856-3865, 2009 63 Lopes LF, West RB, Bacchi LM, van de Rijn M, Bacchi CE: DOG1 for the diagnosis of gastrointestinal stromal tumor (GIST): Comparison between 2 different antibodies. Appl Immunohistochem Mol Morphol 18: 333-337, 2010 64 Macy DW: Canine and feline mast cell tumors: biologic behavior, diagnosis, and therapy. Semin Vet Med Surg (Small Anim) 1: 72-83, 1986 65 Macy DW: Canine mast cell tumors. Vet Clin North Am Small Anim Pract 15: 783-803, 1985 66 McNiel EA, Prink AL, O'Brien TD: Evaluation of risk and clinical outcome of mast cell tumours in pug dogs. Vet Comp Oncol 4: 2-8, 2006 67 Meininger CJ, Yano H, Rottapel R, Bernstein A, Zsebo KM, Zetter BR: The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 79: 958-963, 1992 68 Michels GM, Knapp DW, DeNicola DB, Glickman N, Bonney P: Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases. J Am Anim Hosp Assoc 38: 458-466, 2002 69 Miettinen M, Wang ZF, Lasota J: DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 33: 1401-1408, 2009 70 Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF: Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 30: 1682-1691, 1991 71 Moffett JR, Namboodiri MA: Tryptophan and the immune response. Immunol Cell Biol 81: 247-265, 2003 72 Moore LE, Garrett LD, Debey B, Biller DS: Spinal mast cell tumor in a dog. J Am Anim Hosp Assoc 38: 67-70, 2002 73 Morini M, Bettini G, Preziosi R, Mandrioli L: C-kit gene product (CD117) immunoreactivity in canine and feline paraffin sections. J Histochem Cytochem 52: 705-708, 2004 74 Mullins MN, Dernell WS, Withrow SJ, Ehrhart EJ, Thamm DH, Lana SE: Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). J Am Vet Med Assoc 228: 91-95, 2006 75 Murphy S, Sparkes AH, Blunden AS, Brearley MJ, Smith KC: Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Vet Rec 158: 287-291, 2006 76 Murphy S, Sparkes AH, Smith KC, Blunden AS, Brearley MJ: Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Vet Rec 154: 743-746, 2004 77 Newman SJ, Mrkonjich L, Walker KK, Rohrbach BW: Canine subcutaneous mast cell tumour: diagnosis and prognosis. J Comp Pathol 136: 231-239, 2007 78 Northrup NC, Harmon BG, Gieger TL, Brown CA, Carmichael KP, Garcia A, Latimer KS, Munday JS, Rakich PM, Richey LJ, Stedman NL, Cheng AL, Howerth EW: Variation among pathologists in histologic grading of canine cutaneous mast cell tumors. J Vet Diagn Invest 17: 245-248, 2005 79 Northrup NC, Howerth EW, Harmon BG, Brown CA, Carmicheal KP, Garcia AP, Latimer KS, Munday JS, Rakich PM, Richey LJ, Stedman NL, Gieger TL: Variation among pathologists in the histologic grading of canine cutaneous mast cell tumors with uniform use of a single grading reference. J Vet Diagn Invest 17: 561-564, 2005 80 O'Keefe DA: Canine mast cell tumors. Vet Clin North Am Small Anim Pract 20: 1105-1115, 1990 81 O'Keefe DA, Couto CG, Burke-Schwartz C, Jacobs RM: Systemic mastocytosis in 16 dogs. J Vet Intern Med 1: 75-80, 1987 82 Ozaki K, Yamagami T, Nomura K, Narama I: Prognostic significance of surgical margin, Ki-67 and cyclin D1 protein expression in grade II canine cutaneous mast cell tumor. J Vet Med Sci 69: 1117-1121, 2007 83 Pancholi V: Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 58: 902-920, 2001 84 Pancholi V, Fischetti VA: alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. J Biol Chem 273: 14503-14515, 1998 85 Patnaik AK, Ehler WJ, MacEwen EG: Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. vet pathol 21: 469-474, 1984 86 Poirier VJ, Adams WM, Forrest LJ, Green EM, Dubielzig RR, Vail DM: Radiation therapy for incompletely excised grade II canine mast cell tumors. J Am Anim Hosp Assoc 42: 430-434, 2006 87 Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London CA: Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res 9: 5729-5734, 2003 88 Rebuzzi L, Willmann M, Sonneck K, Gleixner KV, Florian S, Kondo R, Mayerhofer M, Vales A, Gruze A, Pickl WF, Thalhammer JG, Valent P: Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol 115: 320-333, 2007 89 Redlitz A, Fowler BJ, Plow EF, Miles LA: The role of an enolase-related molecule in plasminogen binding to cells. Eur J Biochem 227: 407-415, 1995 90 Reguera MJ, Rabanal RM, Puigdemont A, Ferrer L: Canine mast cell tumors express stem cell factor receptor. Am J Dermatopathol 22: 49-54, 2000 91 Riva F, Brizzola S, Stefanello D, Crema S, Turin L: A study of mutations in the c-kit gene of 32 dogs with mastocytoma. J Vet Diagn Invest 17: 385-388, 2005 92 Rogers KS: Mast cell tumors: dilemmas of diagnosis and treatment. Vet Clin North Am Small Anim Pract 26: 87-102, 1996 93 Romansik EM, Reilly CM, Kass PH, Moore PF, London CA: Mitotic index is predictive for survival for canine cutaneous mast cell tumors. vet pathol 44: 335-341, 2007 94 Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118-8121, 2001 95 Saldanha RG, Molloy MP, Bdeir K, Cines DB, Song X, Uitto PM, Weinreb PH, Violette SM, Baker MS: Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy. J Proteome Res 6: 1016-1028, 2007 96 Scase TJ: Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. Journal of Veterinary Internal Medicine 20: 151, 2006 97 Scase TJ, Edwards D, Miller J, Henley W, Smith K, Blunden A, Murphy S: Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. J Vet Intern Med 20: 151-158, 2006 98 Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000 99 Schwarcz R, Pellicciari R: Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303: 1-10, 2002 100 Seguin B, Leibman NF, Bregazzi VS, Ogilvie GK, Powers BE, Dernell WS, Fettman MJ, Withrow SJ: Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). J Am Vet Med Assoc 218: 1120-1123, 2001 101 Simoes JP, Schoning P, Butine M: Prognosis of canine mast cell tumors: a comparison of three methods. vet pathol 31: 637-647, 1994 102 Simpson AM, Ludwig LL, Newman SJ, Bergman PJ, Hottinger HA, Patnaik AK: Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 224: 236-240, 2004 103 Stanclift RM, Gilson SD: Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 232: 53-62, 2008 104 Stone DM, Jacky PB, Prieur DJ: Chromosomal fragile site expression in dogs: II. Expression in boxer dogs with mast cell tumors. Am J Med Genet 40: 223-229, 1991 105 Strefezzi Rde F, Xavier JG, Catao-Dias JL: Morphometry of canine cutaneous mast cell tumors. vet pathol 40: 268-275, 2003 106 Strefezzi RF, Kleeb SR, Xavier JG, Catao-Dias JL: Prognostic indicators for mast cell tumors. Braz J Vet Pathol 2: 110-121, 2009 107 Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Fujimoto M, Nishisaka T, Okita K, Oka M, Nakamura K: Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics 5: 1686-1692, 2005 108 Thamm DH: mast cell tumors. In: Small animal clinical oncology, eds. Withrow SJMacEwan EG, 3rd ed., pp. 261-282. WB Saunders Co., Philadelphia, 2001 109 Thamm DH, Turek MM, Vail DM: Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci 68: 581-587, 2006 110 Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, Wong TY, Hsiao JR, Wang HP, Shih NY, Wu LW: ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer 46: 1712-1723, 2010 111 Turrel JM, Kitchell BE, Miller LM, Theon A: Prognostic factors for radiation treatment of mast cell tumor in 85 dogs. J Am Vet Med Assoc 193: 936-940, 1988 112 Webster JD, Kiupel M, Kaneene JB, Miller R, Yuzbasiyan-Gurkan V: The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. vet pathol 41: 371-377, 2004 113 Webster JD, Kiupel M, Yuzbasiyan-Gurkan V: Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC Cancer 6: 85, 2006 114 Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M: The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 8: 104-111, 2006 115 Webster JD, Yuzbasiyan-Gurkan V, Miller RA, Kaneene JB, Kiupel M: Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. vet pathol 44: 298-308, 2007 116 Weisse C, Shofer FS, Sorenmo K: Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. J Am Anim Hosp Assoc 38: 71-73, 2002 117 Welle MM, Bley CR, Howard J, Rufenacht S: Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Vet Dermatol 19: 321-339, 2008 118 Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, Sauter G: Prevalence of KIT expression in human tumors. J Clin Oncol 22: 4514-4522, 2004 119 West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn M: The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165: 107-113, 2004 120 Wu CC, Shyu RY, Chou JM, Jao SW, Chao PC, Kang JC, Wu ST, Huang SL, Jiang SY: RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma. Eur J Cancer 42: 557-565, 2006 121 Zemke D, Yamini B, Yuzbasiyan-Gurkan V: Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. vet pathol 39: 529-535, 2002 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36640 | - |
| dc.description.abstract | 肥大細胞瘤(MCTs)是犬最常見的皮膚腫瘤之一。目前最被認可的Patnaik system依據腫瘤細胞的分化程度將其分為三個等級，研究顯示此分級與腫瘤預後有很高的相關性。然而，此分級系統對於肥大細胞瘤的界定仍有模糊地帶，加上第二級肥大細胞瘤在臨床上良惡性表現差異極大，造成臨床預後預測上的困難。此外，雖然部分犬肥大細胞瘤的形成已被證實與KIT過度表現及其基因的突變有密切的關係，但絕大多數的肥大細胞瘤成因都還不清楚。因此，針對可能具有潛在相關性的因子做研究以獲得進一步提供預後或成因的資訊是有其必要性的。
本實驗針對72例犬肥大細胞瘤病例做分析,依照Patnaik system, modified Patnaik system和近年來發表的2-tiere scheme做組織學上的分級，配合免疫化學染色觀察Ki-67、DOG1、KMO和ENO1等新興蛋白質的表現，將其與KIT蛋白的表現、組織病理學的分級以及臨床上的預後做比較。 初步結果可以發現2-tier scheme可以有效的用於區分臨床上表現惡性的腫瘤，然而有一小部分的惡性腫瘤在判定上會發生低估的情形，是這個分級的其中一個缺點。免疫化學染色結果顯示在分化不良的腫瘤中DOG1和KMO的表現皆會下降，且與較短的存活率有關。不表現DOG1的肥大細胞瘤傾向於有較短的復發期；此外，ENO1表現量高的肥大細胞瘤傾向於有較短的存活中位期 (median survival time)。此實驗的初步結果，僅顯示這些新興蛋白質與肥大細胞瘤惡性程度之間之相關性，需要有進一步的研究確立此結果。 | zh_TW |
| dc.description.abstract | Mast cell tumors (MCTs) are one of the most common skin tumors in dogs. Although histological grading was an independent indicator for prognostic prediction, subjectivity in interpretation was considered as a major problem for a relatively low consistency in grading assignment. Moreover, great variation of biological behavior exhibited from grade II MCTs has been occupying a major component of the cases, impeding accurate prognosis prediction and has been regarded as a dilemma for deciding proper treatment strategies. Meanwhile, although KIT overexpression and c-kit mutation have been proven to be related to carcinogenesis of canine MCTs, the etiology remained unknown for most of the cases. Therefore, the necessity of exploring other potential parameters should be considered for advancing current information we’ve got. In this study, we evaluated the new proposed 2-tier grading systems in comparison with Patnaik system and modified Patnaik system. In addition, the emerging proteins including DOG1, KMO, Ki-67 and ENO1 were firstly investigated in the canine species for comparison with histological grading, KIT expression and clinical outcomes.
Current results showed that the use of 2-tier scheme was of benefit for discriminating aggressive tumors, but underestimation could occur in a subset of the tumors. Immunohistochemistry demonstrated the tendency of decreased expression of DOG1 and KMO in poorly-differentiated tumors in association with an overall decreased survival time. Tumors with negative DOG1 expression tended to have a shorter median disease-free interval less than 10 days whereas tumors with strong ENO1 expressions tended to have a shorter median survival time than the others. This observation provided a preliminary data of regulation of the emerging proteins. Further investigation is needed for validation of the preliminary result. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T08:09:02Z (GMT). No. of bitstreams: 1 ntu-100-R96629014-1.pdf: 1818581 bytes, checksum: 6a937e02fb91d8f463eb60907594bcdc (MD5) Previous issue date: 2011 | en |
| dc.description.tableofcontents | 致謝 II
中文摘要 III Abstract IV Chapter 1. Introduction 1 Chapter 2. Background and Literature Review 7 2.1 Mast cell tumors (MCTs) 7 2.1.1 Mast cell histology and physiology 7 2.1.2 Incidence and predilection 8 2.1.3 Clinical presentation and behavior 9 2.1.4 Clinical diagnosis, staging and histological classification 10 2.1.5 Pathogenesis 13 2.1.6 Prognostic factors 15 2.1.7 Treatments 18 2.2 Kynurenine 3-monooxygenase (KMO) 21 2.3 Alpha-enolase (ENO1) 22 2.4 Discovered on GIST-1 (DOG-1) 24 Chapter 3. Materials and Methods 28 3.1 Case collection 28 3.2 Histological evaluation 28 3.3 Immunohistochemistry 29 3.4 Evaluation of KIT, Ki-67, DOG1, ENO1 and KMO immunoreactivity 31 3.5 c-kit mutational analysis 32 3.5.1 DNA purification 32 3.5.2 Polymerase chain reaction (PCR) procedure for detection of ITD mutation in exon 11 of c-kit proto-oncogene 33 3.6 Statistical analysis 33 Chapter4. Results 35 4.1 Patients 35 4.2 Histological grading and comparison between various grading systems 36 4.2.1 Histological grading 36 4.2.2 Correlations between the grading systems and clinical outcome 37 4.3 Immunostaining evaluation 38 4.3.1 KIT expression in comparison with the grading systems, emerging proteins and clinical outcome 38 4.3.2 DOG1 expression in normal canine tissues, canine MCTs and in comparison with the grading systems, emerging proteins and clinical outcome 39 4.3.3 KMO expression in normal canine tissues, canine MCTs and in comparison with the grading systems, emerging proteins and clinical outcome 41 4.3.4 Ki-67 expression in canine MCTs and comparisons with the grading systems, emerging proteins and clinical outcomes 42 4.3.5 ENO1 expression in normal dog tissues and canine MCTs and comparisons with the grading systems, emerging proteins and clinical outcome 42 4.4 ITD c-kit mutation analysis in canine MCTs 43 4.5 Survival data 44 Chapter 5. Discussion 46 Figures 54 Figure 1. Kaplan-Meier survival curve: relationship between Patnaik system and survival rate. 54 Figure 2. Kaplan-Meier survival curve: relationship between modified Patnaik system and survival rate 55 Figure 3. Kaplan-Meier survival curve: relationship between 2-tier system and survival rate 56 Figure 4. Immunohistochemical staining of KIT expression in canine MCTs 57 Figure 5. Kaplan-Meier survival curve: relationship between KIT expression and survival rate 58 Figure 6. DOG1 expression in normal canine tissues, human GISTs and canine MCTs ( incubated with DAB chromogen) 59 Figure 7. Kaplan-Meier survival curve: relationship between DOG1 expression and survival rate 60 Figure 8. The correlations between DOG1 expression and disease-free interval 61 Figure 9. KMO expression in normal canine tissues and canine cutaneous MCTs (incubated with AEC chromogen). 62 Figure 10. Kaplan-Meier survival curve: relationship between KMO expression and survival rate 63 Figure 11. The correlations between differentiation of the neoplastic mast cells and the numbers of Ki-67 immunoreactivity 64 Figure 12. ENO1 expression in human mammary gland tumor, normal canine tissue and canine MCTs 65 Figure 13. Kaplan-Meier survival curve: relationship between ENO1 expression and survival rate 66 Figure 14. ITD c-kit mutation analysis 67 Table 68 Table 1. Clinical staging system for MCTs from World Health Organization * 68 Table 2. Histological classification of Patnaik system 69 Table 3. The correlations between the grading systems and the emerging proteins with survival time 70 Table 4. The correlations between the grading systems and the emerging proteins with tumor recurrence 71 Table 5. KIT expression in canine MCTs: correlations with clinical characteristic and histological grading. 72 Table 6. Correlations between the grading systems and protein expressions of the inclusive cases (n=72) 73 Table 7. KIT expressions in the pMCTs group (n=47) 74 Table 8. The correlations between the grading systems and protein expressions in the pMCTs group 75 Table 9. DOG1 expression in canine MCTs: correlations with clinical characteristic and histological grading. 76 Table 10. DOG1 expressions in the pMCTs group (n=47) 77 Table 11. KMO expression in canine MCTs: correlations with clinical characteristic and histological grading. 78 Table 12. KMO expressions in the pMCTs group (n=47) 79 Table 13. ENO1 expression in canine MCTs: correlations with clinical characteristic and histological grading. 80 References 81 Appendix 92 Appendix 1. 92 Appendix 2. 95 | |
| dc.language.iso | en | |
| dc.subject | 免疫化學染色 | zh_TW |
| dc.subject | 肥大細胞瘤 | zh_TW |
| dc.subject | 組織學分級 | zh_TW |
| dc.subject | KIT | zh_TW |
| dc.subject | DOG1 | zh_TW |
| dc.subject | KMO | zh_TW |
| dc.subject | ENO1 | zh_TW |
| dc.subject | Ki-67 | zh_TW |
| dc.subject | MCTs | en |
| dc.subject | KIT | en |
| dc.subject | IHC | en |
| dc.subject | Histological grading | en |
| dc.subject | Ki-67 | en |
| dc.subject | ENO1 | en |
| dc.subject | KMO | en |
| dc.subject | DOG1 | en |
| dc.title | 犬肥大細胞瘤c-kit 表現與其他新興蛋白質表現之相關性 | zh_TW |
| dc.title | The correlations between the expressions of c-kit and other emerging proteins in canine MCTs | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 99-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 廖泰慶 助理教授(Tai-Ching Liao) | |
| dc.contributor.oralexamcommittee | 張清棟 副教授,李進成 醫師 | |
| dc.subject.keyword | 肥大細胞瘤,組織學分級,免疫化學染色,KIT,DOG1,KMO,ENO1,Ki-67, | zh_TW |
| dc.subject.keyword | MCTs,Histological grading,IHC,KIT,DOG1,KMO,ENO1,Ki-67, | en |
| dc.relation.page | 96 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2011-07-20 | |
| dc.contributor.author-college | 獸醫專業學院 | zh_TW |
| dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
| 顯示於系所單位： | 獸醫學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-100-1.pdf 未授權公開取用 | 1.78 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。